Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationPaul B. Chapman, Grant A. McArthur, Axel Hauschild et al.|New England Journal of Medicine|2011Cited by 7.7k
Pembrolizumab versus Ipilimumab in Advanced MelanomaCaroline Robert, Antoni Ribas|New England Journal of Medicine|2015Cited by 5.8k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockadeMark Ayers, Terrill K. McClanahan, Jared Lunceford et al.|Journal of Clinical Investigation|2017Cited by 3.9k
Inhibition of Mutated, Activated BRAF in Metastatic MelanomaKeith T. Flaherty, Paul B. Chapman, Peter J. O’Dwyer et al.|New England Journal of Medicine|2010Cited by 3.5k
Mutations Associated with Acquired Resistance to PD-1 Blockade in MelanomaJesse M. Zaretsky, Antoni Ribas|New England Journal of Medicine|2016Cited by 3.1k